Colt Ventures
VC Fund
Dallas, United States
Colt Ventures is a VC fund in Dallas focused on Biotechnology and Health Care. Colt Ventures proving a broad range of investment activities and has the flexibility to invest in a wide variety of asset classes.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Colt Ventures invests in
Stages Colt Ventures invests in
Countries Colt Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Darren Blanton
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 7 (54%)
- Health Care 5 (38%)
- Biopharma 3 (23%)
- Therapeutics 3 (23%)
- Pharmaceutical 2 (15%)
Stage
- Series B 6 (46%)
- Series A 3 (23%)
- Series C 1 (8%)
- Funding Round 1 (8%)
Country
- United States 8 (62%)
- Canada 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Darren Blanton
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alterome Therapeutics
|
Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $132M / Series B / Apr 03, 2024 | |
BlossomHill Therapeutics
|
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $100M / Series B / Jan 02, 2024 | |
Odyssey Therapeutics
|
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $101M / Series C / Dec 05, 2023 | |
|
Alterome Therapeutics
|
Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $35M / Series A / Nov 02, 2022 | |
|
Odyssey Therapeutics
|
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $218M / Series A / Dec 07, 2021 | |
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M / Series B / Oct 21, 2021 | |
EBY
|
EBY is a membership-based company driving profits with purpose. EBY repositions underwear as a tool for empowerment rather than one of seduction. In fact, 10% of net sales go to the Seven Bar Foundation to empower women out of poverty and into business via microfinance with a small loan, what we call a first break, that can be as little as $80or as large as $7,000. This loan enables an underprivileged woman to start or grow her business. As she becomes self-sufficient the cycle of poverty is broken. Loans are repaid and passed to another woman, creating a multiplier effect. EBY consistently fuels this loop so that it never ends, creating more first breaks and more bionic women. We’re not about token donations, but rather long-term solutions. | $6M / Series A / Aug 30, 2021 | |
Rumble
|
Rumble is an open video management system for publishers and creators. It develops a rights management video platform providing visitors to access content through the internet and offers the opportunity for users to submit text, pictures, video, and other content for posting on the website. | Venture - Series Unknown / May 20, 2021 | |
Erasca
|
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations,providing patients with new potential solutions to not just treat but cure cancer.Erasca was founded in 2018 and is headquartered in San Diego, California. | $200M / Series B / Apr 27, 2020 | |
|
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M / Series A / Mar 26, 2020 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Colt Ventures invest in?
Colt Ventures invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Colt Ventures?
Public channels for Colt Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Colt Ventures?
The team at Colt Ventures includes Darren Blanton (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
